Investor Relations

Tekmira Pharmaceuticals Corporation (NASDAQ:TKMRTSX:TKM) is a leading RNA interference (RNAi) therapeutics company. With more than 14 years of industry experience, Tekmira has established itself as a global leader in the RNAi field. Tekmira has a diverse pipeline of product candidates in development to treat serious human diseases such as cancer and viral infections like Hepatitis B and Ebola. The company is advancing the development of novel drugs in areas where there is a significant unmet medical need and commercial opportunity. Tekmira also licenses its leading LNP delivery technology to partners around the world.

View all »   RSSRecent Releases

Feb 25, 2015
Tekmira Announces Update to Its Proxy Circular on the Proposed Business Combination With OnCore Biopharma Inc.

Feb 12, 2015
Tekmira to Present at RBC Capital Markets' Healthcare Conference

View all »Events & Presentations

Feb 24, 2015 at 3:05 PM ET
RBC Capital Markets 2015 Healthcare Conference

Jan 12, 2015 at 5:30 AM PT
Tekmira Pharmaceuticals and OnCore Biopharma Conference Call and Webcast